WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced the addition of Bhooshi De Silva as senior vice president of corporate development and strategy to its executive leadership team. De Silva will focus on key strategic initiatives vital to supporting PPD’s growth and client success, including corporate development, strategy and mergers and acquisitions.
“Bhooshi’s vision and expertise will be invaluable in our efforts to grow our business and successfully meet the evolving needs of our clients,” said David Simmons, PPD’s chairman and chief executive officer. “He comes to PPD well-prepared to help us navigate the challenges of the changing biopharmaceutical landscape, while developing and executing a strategy for our company’s continued success.”
With 15 years of experience in the biopharmaceutical industry, De Silva brings significant leadership expertise. He started his career at Pfizer, holding roles across the research and development and commercial organizations in portfolio management, strategy and operations. His responsibilities included overseeing the development and strengthening of analytical frameworks and decision-making processes.
In 2009, De Silva was named vice president of business development evaluation and strategy, leading a team in the evaluation of licensing, acquisitions and corporate strategic initiatives for Pfizer. Most recently, he served as head of business development, corporate strategy and international teams at Optimer Pharmaceuticals.
De Silva holds degrees in finance, economics and engineering from Stanford University, London School of Economics and Imperial College of Science & Technology in London.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s new senior vice president, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.